Do we need another NSAID instead of indomethacin for treatment of ductus arteriosus in preterm infants?

Acta Paediatr. 2003 Sep;92(9):996-9.


Up until now indomethacin is the most extensively evaluated non-steroidal anti-inflammatory drug (NSAID) in neonatal medicine. If used with due consideration to the physiologic role of prostaglandins, a 90 success rate can be reached and serious adverse drug effects prevented.

Conclusion: The results reported by Bellander et al. support the idea that we do not need to study other substances of the same therapeutic class, with the same target--cyclooxygenase--in the prostaglandin cascade and with a similar pharmacological profile. Instead, indomethacin treatment regimes should be further improved with respect to their efficacy and safety.

Publication types

  • Comment

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Enteral Nutrition*
  • Humans
  • Indomethacin / therapeutic use*
  • Infant, Newborn
  • Infant, Premature
  • Milk, Human


  • Anti-Inflammatory Agents, Non-Steroidal
  • Indomethacin